The Physiologically Difficult Airway
RCEM CPD in London this week and I am off to give a talk on this interesting and ever developing topic. Hope to see some of you there. Although I …
JC: Keep on blocking in the free world. Remi vs. NMB for RSI. St Emlyn’s
Dan Horner reviews the JAMA paper on remifentanyl vs. neuromuscular blocking agents (NMBs) for RSI. #FOAMed @stemlyns
TBI: The Final Frontier…
Summer hols and quiet times for many of us at present, so apologies for lack of posts. There is always stuff going on in the background however, and several of …
Designer medicine for suspected DVT: the 4D study. St Emlyn’s
Do you want to halve your ultrasound referral rate for suspected Deep Vein Thrombosis? You do? How marvellous. Reducing referral rates from ED for a specialist test like vascular sonography …
Designer medicine for suspected DVT: the 4D study. St Emlyn’s Read More »
Learning from airway management in the ED: UK Perspective
This is the transcript for an invited talk at the recent Difficult Airway Society (DAS) 2021 virtual conference. It was lovely to be invited and great of the organisers to …
Learning from airway management in the ED: UK Perspective Read More »
JC: Thromboprophylaxis for the non ICU hospitalised COVID-19 patient. St Emlyn’s
Back in March we reported on a pre-print trial of thromboprophylaxis of ICU patients. The results suggested that there was no benefit for therapeutic dose anticoagulation in COVID19 as a prophylactic strategy for …
JC: Thromboprophylaxis for the non ICU hospitalised COVID-19 patient. St Emlyn’s Read More »
Post-vaccine headache in the Emergency Department: what you need to know. St Emlyn’s
I am sure you all saw the recent MHRA press release and guidance, discussing the issue of a possible link between the AstraZeneca COVID19 vaccine and a rare type of …
Post-vaccine headache in the Emergency Department: what you need to know. St Emlyn’s Read More »
Tocilizumabulous? A special offer on IL-6 with Tocilizumab.
It’s very rare we produce three instalments on one particular drug for one particular condition, and certainly not within such a short time frame. However, tocilizumab has been worth it. …
Tocilizumabulous? A special offer on IL-6 with Tocilizumab. Read More »